MK-7622 is used as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for the symptomatic treatment of participants with mild to moderate Alzheimer's Disease (AD). Now MK-7622 is in phase II clinical trials by Merck.
Description: Verubecestat(MK-8931) is a small-molecule inhibitor of beta-secretase cleaving enzyme (BACE)1 and BACE2 in development by Merck for the treatment of Alzheimers Disease.